Jeremy Bleicher
Endocrinology, Diabetes & Metabolism · North Miami Beach, FLNPI 1053656561
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,497 and has fallen 58.7% since, to $618 in 2025.
Across 248 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$867
- Insulet Corporation$636
- Novo Nordisk$504
- Sanofi-aventis U.S. LLC$500
- Abbott$410
- Mannkind Corporation$336
- plus $2K from 25 others
Across 359 payments — averaging $6346.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$1.7M
- Endo Pharmaceuticals Inc.$357K
- BD$184K
- Jazz Pharmaceuticals Inc.$27K
- Modernatx, Inc.$8K
What the payments were for
- Food & beverage$5,112100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 40 | $867 |
| Insulet Corporation | 25 | $636 |
| Novo Nordisk | 26 | $504 |
| Sanofi-aventis U.S. LLC | 21 | $500 |
| Abbott | 25 | $410 |
| Mannkind Corporation | 18 | $336 |
| AbbVie | 19 | $263 |
| Boehringer Ingelheim | 12 | $255 |
| Valeritas, Inc. | 4 | $156 |
| Johnson & Johnson | 15 | $140 |
| Dexcom, Inc. | 2 | $137 |
| Corcept Therapeutics | 3 | $97 |
| Zealand Pharma US, Inc. | 2 | $90 |
| Amgen(2 entities) | 4 | $74 |
| Cequr Corporation | 2 | $73 |
| Tandem Diabetes Care, Inc. | 3 | $70 |
| BD | 4 | $67 |
| Kyowa Kirin, Inc. | 3 | $59 |
| AstraZeneca | 3 | $57 |
| IBSA Pharma Inc. | 2 | $46 |
| Radius Health, Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Sequel Med Tech, LLC | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $27 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Averitas Pharma Inc. | 1 | $24 |
| Ascendis Pharma Endocrinology Inc | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$133
- V-GO$117
- DEXCOM CGM$115
How this compares
$5,126 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $136,146 |
| MounjaroTirzepatide | 46 | $52,005 |
| TrulicityDulaglutide | 29 | $43,545 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $41,200 |
| JardianceEmpagliflozin | 22 | $35,313 |
| RybelsusSemaglutide | 28 | $30,032 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $22,943 |
| FarxigaDapagliflozin Propanediol | 23 | $20,090 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $19,201 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $18,831 |
| Novolog FlexpenInsulin Aspart | 116 | $15,358 |
| JanuviaSitagliptin Phosphate | 12 | $15,114 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $14,889 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $14,647 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 165 | $13,827 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $504 | $171,807199 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $867 | $102,893106 claims |
| Boehringer IngelheimJardiance | $255 | $35,31322 claims |
| AstraZenecaFarxiga | $57 | $20,09023 claims |
| MerckJanuvia | $15 | $15,11412 claims |
| Sanofi-aventis U.S. LLCLantus | $500 | $3,32730 claims |
| AbbVieSynthroid | $263 | $2,57721 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $1,189153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in North Miami Beach
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.